

SHEBA CANCR RESEACH CENTER - PUBLICATINS

Year 2009

1. Besser M, Schallmach E, Oved K, Treves A, Markel G, Reiter Y, Schachter J **Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.** *Cytotherapy*. 2009 Jan; 11:(2):206-217. (IF 3.5)
2. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, Orenstein A, Berger R, Schachter J. **Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.** *Immunology*. 2009 Feb; 126(2):186-200. (IF 3.3)
3. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajdúch M, Jacob-Hirsch J, Amariglio N, Krupsky M, Simansky DA, Ram Z, Pfeffer R, Galanter I, Steinberg DM, Ben-Dov I, Rechavi G, Izraeli S. **The Expression of Three Genes in Primary Non-Small Cell Lung Cancer Is Associated with Metastatic Spread to the Brain.** *Clin Cancer Res*. 2009 Mar 1; 15(5):1755-61. (IF 6.5)
4. Zilberman DE, Safran M, Paz N, Amariglio N, Simon A, Fridman E, Kleinmann N, Ramon J, Rechavi G. **Does RNA editing play a role in the development of urinary bladder cancer?** *Urol Oncol*. 2009 Jan 29. [Epub ahead of print](IF 2.7)
5. Alon S, Eisenberg E, Jacob-Hirsch J, Rechavi G, Vatine G, Toyama R, Coon SL, Klein DC, Gothilf Y. **A new cis-acting regulatory element driving gene expression in the zebrafish pineal gland.** *Bioinformatics*. 2009 Mar 1;25(5):559-62. (IF 4.3)
6. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, D'Orazi G. **Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.** *Exp Cell Res*. 2009 Jan 1;3 15(1):67-75. (IF 3.695)
7. Vagima Y, Avigdor A, Goichberg P, Shvitiel S, Tesio M, Kalinkovich A, Golan K, Dar A, Kollet O, Petit I, Perl O, Rosenthal E, Resnick I, Hardan I, Gellman YN, Naor D, Nagler A, Lapidot T. **MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization.** *J Clin Invest*. 2009 Mar;119(3):492-503. (IF 2.8)
8. Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M. **Inhibition of Transforming Growth Factor beta Signaling by Halofuginone as a Modality for Pancreas Fibrosis Prevention.** *Pancreas*. 2009 May; 38(4):427-35. (IF 2.7)
9. Shimoni A, Leiba M, Schleuning M, Martineau G, Renaud M, Koren-Michowitz M, Ribakovski E, le Coutre P, Arnold R, Guilhot F, Nagler A. **Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.** *Leukemia*. 2009 Jan : 23(1):190-4. (IF 8.6)
10. Malinge S, Izraeli S, Crispino JD. **Insights into the manifestations, outcomes and mechanisms of leukemogenesis in Down syndrome.** *Blood*. 2009 Mar 19;113(12):2619-28. (IF 2.4)

11. Yang JL, Hong KC, Schachter J, Moncada J, Lekew T, House JI, Zhou Z, Neuwelt MD, Rutar T, Halfpenny C, Shah N, Whitcher JP, Lietman TM. **Detection of Chlamydia trachomatis ocular infection in trachoma-endemic communities by rRNA amplification.** *Invest Ophthalmol Vis Sci.* 2009 Jan; 50(1):90-4.(IF 3.5)
12. Leibovici J, Itzhaki O, Kaptzan T, Skutelsky E, Sinai J, Michowitz M, Asfur R, Siegal A, Huszar M, Schiby G. **Designing ageing conditions in tumour microenvironment-A new possible modality for cancer treatment.** *Mech Ageing Dev.* 2009 Jan-Feb; 130(1-2):76-85. (IF 3.9)
13. Nadu A, Kleinmann N, Laufer M, Dotan Z, Winkler H, Ramon J. **Laparoscopic partial nephrectomy for central tumors: analysis of perioperative outcomes and complications.** *J Urol.* 2009 Jan; 181(1):42-7. (IF 0.9)
14. Geva R, Jiveliouk I, Inbar M, Meller I, Friedman E, Merimsky O. **The co-occurrence of breast cancer and soft tissue sarcoma in a single cohort series.** *Am J Clin Oncol.* 2009 Feb;32(1):34-7 (IF 1.8)
15. Besser MJ, Shapira R, Treves AJ, Zippel D, Itzhaki O, Schallach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. **Minimally – cultured or selected autologous tumor infiltrating lymphocytes following a lymphodepleting chemotherapy Regimen in Metastatic Melanoma Patients** *J Immunother.* 2009 May; 32(4):415-23.(IF 3.7)
16. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G. **Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient.** *PLoS Med.* 2009 Feb 17; 6(2):e29. (IF 12.2)
17. Markel G, Choen Sinai T, Besser MJ, Kfir O, Itzhaki O, Seidman R, Treves AJ, Fridman E, Keisari Y, Dotan Z, Ramon J, Schachter J. **Preclinical Evaluation of Adoptive Cell Therapy for Metastatic Renal Cell Carcinoma Patients.** *Anticancer Research* 2009 Jan; 29(1):145-54.(IF 1.3)
18. Oved K, Eden E, Akerman M, Noy R, Wolchinsky R, Itzhaki O, Schallmach E, Kubi A, Zabari N, Schachter J, Alon U, Mandel-Gutfreund Y, Besser MJ, Reiter Y. **A Systems Approach for Understanding and Controlling the Reactivity of Immune Cell Populations against Cancer.** *Molecular Systems Biology* 2009 5:265.
19. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. **Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Non-Squamous Non-Small-Cell Lung Carcinoma.** *J Clin Oncol.* 2009 Apr 20;27(12):2030-7. (IF 1.8)
20. Stanchesu R, Betts DR, Rechavi G, Amariglio N, Trakhtenbrot L. **Involvement of der(12)t(12;21)(p13;q22) and as well as additional rearrangements of chromosome 12 homolog in ETV6/RUNX1-positive acute lymphoblastic leukemia.** *Cancer Genet Cytogenet.* 2009 Apr 1; 190(1):26-32. (IF 1.4)
21. Sharabi K, Hurwitz A, Simon AJ, Beitel GJ, Morimoto RI, Rechavi G, Sznajder JI, Gruenbaum Y. **Elevated CO2 levels affect development, motility, and fertility and extend life span in Caenorhabditis elegans.** *Proc Natl Acad Sci U S A.* 2009 Mar 10; 106(10):4024-9. (IF

22. Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M. **Cancer cells suppress p53 in adjacent fibroblasts** *Oncogene*. 2009 Feb 12; 28(6):933-6. (IF 7.2)
23. Arien-Zakay H, Lecht S, Bercu MM, Tabakman R, Kohen R, Galski H, Nagler A, Lazarovici P. **Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors.** *Exp Neurol*. 2009 Mar; 216(1):83-94.(IF 4.0)
24. Stanevsky A, Goldstein G, Nagler A. **Umbilical cord blood transplantation: Pros, cons and beyond.** *Blood Rev*. 2009 23(5):199-204.(IF 7.8)
25. Abraham M, Beider K, Wald H, Weiss ID, Zipori D, Galun E, Nagler A, Eizenberg O, Peled A. **The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation.** *Leukemia*. 2009 23(8):1378-88.(IF 8.6)
26. Beider K, Abraham M, Begin M, Wald H, Weiss ID, Wald O, Pikarsky E, Abramovitch R, Zeira E, Galun E, Nagler A, Peled A. **Interaction between CXCR4 and CCL20 pathways regulates tumor growth.** *PLoS ONE*. 2009; 4(4):e5125.
27. Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, Chander G, Hengst S, Pfeffer R, Chechick A, Hanannel A, Dogadkin O, Catane R. **Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study.** *Ann Surg Oncol*. 2009 Jan; 16(1):140-6.(IF 3.9)
28. Urban D, Cherny N, Catane R. **The management of cancer pain in the elderly.** *Crit Rev Oncol Hematol*. 2010 Feb; 73(2):176-183.
29. Ganmore I, Smooha G, Izraeli S. **Constitutional aneuploidy and cancer predisposition.** *Hum Mol Genet*. 2009 Apr 15;18(R1):R84-93
30. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cavé H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grümayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Möricke A, Schrappe M, Alonso CN, Schäfer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R. **New insights to the MLL recombinome of acute leukemias** *Leukemia*. 2009 23(8):1490-9. (IF 8.6)
31. Horev-Azaria L, Eliav S, Izigov N, Pri-Chen S, Mirelman D, Miron T, Rabinkov A, Wilchek M, Jacob-Hirsch J, Amariglio N, Savion N. **Allicin up-regulates cellular glutathione level in vascular endothelial cells.** *Eur J Nutr*. 2009 Mar; 48(2):67-74.(IF 1.9)
32. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. **Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.** *J Oral Maxillofac Surg*. 2009 Apr; 67(4):850-5.
33. Vrijheid M, Richardson L, Armstrong BK, Auvinen A, Berg G, Carroll M, Chetrit A, Deltour I, Feychting M, Giles GG, Hours M, Iavarone I, Lagorio S, Lönn S, McBride M, Parent ME, Sadetzki S, Salminen T, Sanchez M, Schlehofer B, Schüz J, Siemiatycki J, Tynes T, Woodward A, Yamaguchi N, Cardis E. **Quantifying the impact of selection bias caused by**

- nonparticipation in a case-control study of mobile phone use.** *Ann Epidemiol.* 2009 Jan; 19(1):33-41.(IF 2.6)
34. Sadetzki S, Mandelzweig L. **Childhood exposure to external ionising radiation and solid cancer risk.** *Br J Cancer.* 2009 Apr 7; 100(7):1021-5.
 35. Zilberman DE, Cohen Y, Amariglio N, Fridman E, Ramon J, Rechavi G **AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma.** *Cancer Genet Cytogenet.* 2009 May; 191(1):34-7.
 36. Oved K, Eden E, Akerman M, Noy R, Wolchinsky R, Izhaki O, Schallmach E, Kubi A, Zabari N, Schachter J, Alon U, Mandel-Gutfreund Y, Besser MJ, Reiter Y. **Predicting and controlling the reactivity of immune cell populations against cancer.** *Mol Syst Biol.* 2009;5:265.(IF 12.2)
 37. Mesilaty-Gross S, Anikster Y, Vilensky B, Wolf I, Phillip M, Gat-Yablonski G **Different patterns of human serum procollagen C-proteinase enhancer1 (PCPE1).** *Clin Chim Acta.* 2009 May; 403(1-2):76-80.(IF 3.0)
 38. Korach J, Machtinger R, Perri T, Vicus D, Segal J, Fridman E, Ben-Baruch G **Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge.** *Acta Obstet Gynecol Scand.* 2009; 88(3):355-8.
 39. Nadu A, Kleinmann N, Laufer M, Dotan Z, Winkler H, Ramon J. **Laparoscopic partial nephrectomy for central tumors: analysis of perioperative outcomes and complications.** *J Urol.* 2009 Jan; 181(1):42-7.(IF 1.0)
 40. Cortesi M, Chechik R, Breskin A, Vartsky D, Ramon J, Raviv G, Volkov A, Fridman E. **Evaluating the cancer detection and grading potential of prostatic-zinc imaging: a simulation study.** *Phys Med Biol.* 2009 Feb 7; 54(3):781-96. (IF 2.8)
 41. Welter-Stahl L, da Silva CM, Schachter J, Persechini PM, Souza HS, Ojcus DM, Coutinho-Silva R. **Expression of purinergic receptors and modulation of P2X(7) function by the inflammatory cytokine IFNgamma in human epithelial cells.** *Biochim Biophys Acta.* 2009 May; 1788(5):1176-87.
 42. Gluck I, Simon AJ, Catane R, Pfeffer R, Schachter J, Rechavi G, Bar J. **Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients.** *Melanoma Res.* 2009 Aug; 19(4):199-202.(IF 2.3)
 43. Mashiah J, Brenner S, Pessach Y, Barak V, Schachter J. **Differences in Cytokine Levels in Melanoma Patients with and without Redness (Brenner Sign).** *Anticancer Res.* 2009 May; 29(5):1793-6.(IF 1.4)
 44. Yarom N, Shani T, Amariglio N, Taicher S, Kaplan I, Vered M, Rechavi G, Trakhtenbrot L, Hirshberg A. **Chromosomal numerical aberrations in oral lichen planus.** *J Dent Res.* 2009 May; 88(5):427-32.(IF 3.1)
 45. Arien-Zakay H, Lecht S, Bercu MM, Amariglio N, Rechavi G, Galski H, Lazarovici P, Nagler A. **Interferon-gamma-induced neuronal differentiation of human umbilical cord blood-derived progenitors.** *Leukemia.* 2009 Oct; 23(10):1790-800.(IF 8.6)
 46. Salek-Ardakani S, Smootha G, de Boer J, Sebire NJ, Morrow M, Rainis L, Lee S, Williams O, Izraeli S, Brady HJ. **ERG is a megakaryocytic oncogene** *Cancer Res.* 2009 Jun 1; 69(11):4665-73.(IF 4.5)
 47. Picard C, McCarl CA, Papolos A, Khalil S, Lüthy K, Hivroz C, LeDeist F, Rieux-Laucat F, Rechavi G, Rao A, Fischer A, Feske S. **STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity.** *N Engl J Med.* 2009 May 7; 360(19):1971-80.

48. Avivi I, Avraham S, Koren-Michowitz M, Zuckerman T, Aviv A, Ofra Y, Benyamini N, Nagler A, Rowe JM, Nagler RM. **Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT.** *Bone Marrow Transplant.* 2009 May;43(10):801-6.
49. Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B. **Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.** *Blood.* 2009 May 7; 113(19):4497-504.(IF 2.4)
50. Dezorella N, Pevsner-Fischer M, Deutsch V, Kay S, Baron S, Stern R, Tavor S, Nagler A, Naparstek E, Zipori D, Katz BZ. **Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.** *Exp Cell Res.* 2009 Jul 1; 315(11):1904-13.(IF 3.9)
51. Chevallier P, Labopin M, Nagler A, Ljungman P, Verdonck LF, Volin L, Zander AR, Finke J, Socie G, Cordonnier C, Harousseau JL, Mohty M, Rocha V. **Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.** *Bone Marrow Transplant.* 2009 Nov; 44(9):589-94.
52. Natan D, Nagler A, Arav A. **Freeze-drying of mononuclear cells derived from umbilical cord blood followed by colony formation.** *PLoS ONE.* 2009; 4(4):e5240.
53. Halfon S, Paul M, Steinberg D, Nagler A, Arenshtam A, Kijel D, Polacheck I, Srebnik M. **High power accelerator-based boron neutron capture with a liquid lithium target and new applications to treatment of infectious diseases** *Appl Radiat Isot.* 2009 Jul; 67(7-8 Suppl):S278-81. (IF 1.1)
54. Ostrovsky O, Korostishevsky M, Shafat I, Mayorov M, Ilan N, Vlodavsky I, Nagler A. **Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation.** *J Leukoc Biol.* 2009 86(2):445-55.
55. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, Loewenthal R, Orenstein A, Nagler A, Schachter J. **Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.** *PLoS ONE.* 2009; 4(5):e5597.
56. Nefussy B, Artamonov I, Deutsch V, Naparstek E, Nagler A, Drory VE **Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study.** *Amyotroph Lateral Scler.* 2009 May 15:1-7.
57. Kröger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A. **Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.** *Exp Hematol.* 2009 37(7); 791-8.(IF 3.2)

58. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser M, J Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J. **Systemic dysregulation of CEACAM1 in the melanoma patients.** *Cancer Immunol Immunother.* 2009 Jul 25. [Epub ahead of print]
59. Toledano M, Kozar E, Goldstein LH, Abu-Kishk I, Bar-Haim A, Siman-Tov Y, Rechavi M, Rechavi G, Weizer-Stern O, Berkovitch M. **Hepcidin in acute iron toxicity.** *Am J Emerg Med.* 2009 Sep; 27(7):761-4.(IF 1.2)
60. Seksenyan A, Ron-Harel N, Azoulay D, Cahalon L, Cardon M, Rogeri P, Ko MK, Weil M, Bulvik S, Rechavi G, Amariglio N, Konen E, Koronyo-Hamaoui M, Somech R, Schwartz M. **Thymic Involution in Amyotrophic Lateral Sclerosis.** *J Cell Mol Med.* 2009 Jul 24. [Epub ahead of print](IF 5.1)
61. Osenberg S, Dominissini D, Rechavi G, Eisenberg E. **Widespread cleavage of A-to-I hyperediting substrates.** *RNA.* 2009 Sep;15(9):1632-9.
62. Yarom N, Shani T, Amariglio N, Taicher S, Kaplan I, Vered M, Rechavi G, Trakhtenbrot L, Hirshberg A. **Chromosomal numerical aberrations in oral lichen planus.** *J Dent Res.* 2009 May; 88(5):427-32.(IF 3.1)
63. Salek-Ardakani S, Smootha G, de Boer J, Sebire NJ, Morrow M, Rainis L, Lee S, Williams O, Izraeli S, Brady HJ. **ERG is a megakaryocytic oncogene.** *Cancer Res.* 2009 Jun 1; 69(11):4665-73.(IF 4.5)
64. Cherny N, Catane R, Schrijvers D, Kloke M, Strasser F. **European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program.** *Melanoma Res.* 2009 Aug; 19(4):199-202. (IF 4.9)
65. Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R, Kaufman B. **Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients.** *Am J Clin Oncol.* 2009 Jun 26. [Epub ahead of print](IF 1.8)
66. Urban D, Catane R. **Serum tumor markers in oncology.** *Isr Med Assoc J.* 2009 Feb; 11(2):103-4.(IF 0.6)
67. Osenberg S, Dominissini D, Rechavi G, Eisenberg E **Widespread cleavage of A-to-I hyperediting substrates.** *RNA.* 2009 Sep; 15(9):1632-9.
68. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. **Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.** *PLoS One.* 2009 Aug 28; 4(8):e6819.
69. Mandel M, Achiron A, Tuller T, Barliya T, Rechavi G, Amariglio N, Loewenthal R, Lavie G. **Clone clusters in autoreactive CD4 T-cell lines from probable multiple sclerosis patients form disease-characteristic signatures.** *Immunology.* 2009 Oct; 128(2):287-300.(IF 3.4)
70. Barak M, Levanon EY, Eisenberg E, Paz N, Rechavi G, Church GM, Mehr R. **Evidence for large diversity in the human transcriptome created by Alu RNA editing.** *Nucleic Acids Res.* 2009 Nov; 37(20):6905-15. Sep 8.(IF 6.9)
71. Somech R, Simon AJ, Lev A, Dalal I, Spierer Z, Goldstein I, Nagar M, Amariglio N, Rechavi G, Roifman CM. **Reduced central tolerance in Omenn syndrome leads to immature self-reactive oligoclonal T cells.** *J Allergy Clin Immunol.* 2009 Oct; 124(4):793-800. Sep 18.
72. Idelson M, Alper R, Obolensky A, Ben-Shushan E, Hemo I, Yachimovich-Cohen N, Khaner H, Smith Y, Wiser O, Gropp M, Cohen MA, Even-Ram S,

- Berman-Zaken Y, Matzrafi L, Rechavi G, Banin E, Reubinoff B. **Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells.** *Cell Stem Cell*. 2009 Oct 2 ;5(4):396-408.(IF 16.8)
73. Lev A, Amariglio N, Levy Y, Spirer Z, Anikster Y, Rechavi G, Dekel B, Somech R. **Molecular assessment of thymic capacities in patients with Schimke immuno-osseous dysplasia.** *Clin Immunol*. 2009 Dec;133(3):375-81(IF 3.6)
 74. Stark B, Avrahami G, Nirel R, Abramov A, Attias D, Ballin A, Bielorai B, Burstein Y, Gavriel H, Elhasid R, Kapelushnik J, Stoecker D, Toren A, Wientraub M, Yaniv I, Izraeli S. **Extended triple intrathecal therapy in children with T-cell acute lymphoblastic leukaemia: a report from the Israeli National ALL-Studies.** *Br J Haematol*. 2009 Oct; 147(1):113-24. Epub 2009 Aug 19
 75. Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R, Kaufman B. **Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients.** *Am J Clin Oncol*. 2009 Jun 26. [Epub ahead of print](IF 1.8)
 76. Cherny N, Catane R, Schrijvers D, Kloke M, Strasser F. **European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program.** *Ann Oncol*. 2009 Aug 4. [Epub ahead of print (IF 4.9)
 77. Shimoni A, Nagler A. **Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?** *Leuk Lymphoma*. 2009 Sep;50(9):1395-6
 78. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D'Orazi G. **HIPK2 modulates p53 activity towards pro-apoptotic transcription.** *Mol Cancer*. 2009 Oct 14;8:85 (IF 5.4)
 79. Lev A, Amariglio N, Spirer Z, Katz U, Bielorai B, Rechavi G, Somech R. **Specific self-antigen-driven immune response in pericardial effusion as an isolated GVHD manifestation.** *Bone Marrow Transplant*. 2009 Nov 16. [Epub ahead of print]
 80. Mohty M, Rocha V, Chevallier P, Harousseau JL, Nagler A. **Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later.** *Curr Opin Oncol*. 2009 Jun; 21 Suppl 1:S1.(IF 4.1)
 81. Kroger N, Holler E, Kobbe G, Bornhaeuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM. **Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).** *Blood*. 2009 Dec 17;114(26):5264-70. (IF 5.7)
 82. Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. **adioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.** *Oncologist*. 2009;14 Suppl 2:41-51 (IF 6.6)
 83. Nagler A, Andolsek K, Padmore JS. **The unintended consequences of portfolios in graduate medical education.** *Acad Med*. 2009 Nov; 84(11):1522-6. (IF 1.9)

84. Cherny N, Catane R, Schrijvers D, Kloke M, Strasser F. **European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program.** *Ann Oncol.* 2009 Oct;23(7):581-93. (IF 4.9)
85. Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B. **Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.** *Oncogene.* 2009 Oct 5. [Epub ahead of print](IF 7.2)
86. Menczer J, Chetrit A, Sadetzki S; National Israel Ovarian Cancer Group. **The effect of symptom duration in epithelial ovarian cancer on prognostic factors.** *Arch Gynecol Obstet.* 2009 Jun;279(6):797-801. (IF 0.7)
87. Vrijheid M, Richardson L, Armstrong BK, Auvinen A, Berg G, Carroll M, Chetrit A, Deltour I, Feychting M, Giles GG, Hours M, Iavarone I, Lagorio S, Lönn S, McBride M, Parent ME, Sadetzki S, Salminen T, Sanchez M, Schlehofer B, Schüz J, Siemiatycki J, Tynes T, Woodward A, Yamaguchi N, Cardis E. **Quantifying the impact of selection bias caused by nonparticipation in a case-control study of mobile phone use.** *Ann Epidemiol.* 2009 Jan;19(1):33-41.(IF 2.6)
88. Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, Ben-Baruch G. **Uterine leiomyosarcoma: does the primary surgical procedure matter?** *Int J Gynecol Cancer.* 2009 Feb;19(2):257-60 (IF 1.9)
89. Mandelzweig L, Novikov I, Sadetzki S. **Smoking and risk of glioma: a meta-analysis.** *Cancer Causes Control.* 2009 Jul 1. [Epub ahead of print](IF
90. Freedman LS, Oberman B, Sadetzki S. **Using time-dependent covariate analysis to elucidate the relation of smoking history to Warthin's tumor risk.** *Am J Epidemiol.* 2009 Nov 1; 170(9):1178-85. (IF 5.5)
91. Menczer J, Chetrit A, Sadetzki S; National Israel Ovarian Cancer Group. **Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel.** *Eur J Gynaecol Oncol.* 2009; 30(4):375-8. (IF 0.6)
92. Menczer J, Barchana M, Chetrit A, Liphshitz I, Sadetzki S. **Incidence rates of cervical carcinoma among first- and second-generation women of North African origin in Israel.** *Int J Gynecol Cancer.* 2009 Dec;19(9):1606-9 (IF 1.9)
93. Bar J, Herbst RS, Onn A. **Targeted drug delivery strategies to treat lung metastasis** *Expert Opin Drug Deliv.* 2009 Oct;6(10):1003-16.
94. Aronovich A, Tchorsh D, Shezen E, Rosen C, Klionsky Y, Cohen S, Tal O, Martinowitz U, Katchman H, Eventov-Friedman S, Amariglio N, Jacob-Hirsch J, Rechavi G, Reisner Y **Enhancement of pig embryonic implants in factor VIII KO mice: a novel role for the coagulation cascade in organ size control.** *PLoS One.* 2009 Dec 21; 4(12):e8362.
95. Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S, Plon SE, Basso G, Pession A, Rabin KR. **Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.** *Br J Haematol.* 2009 Mar; 144(6):930-2.
96. Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S, Cohen-Armon M. **A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.** *Breast Cancer Res.* 2009 Nov 9; 11(6):R78.(IF 5.1)

97. Stark B, Nirel R, Avrahami G, Abramov A, Attias D, Ballin A, Bielorai B, Burstein Y, Gavriel H, Elhasid R, Kapelushnik J, Sthoeger D, Toren A, Wientraub M, Yaniv I, Izraeli S. **Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98.** *Leukemia*. 2009 Dec 17. [Epub ahead of print](IF 8.6)
98. Mesilaty-Gross S, Anikster Y, Vilensky B, Wolf I, Phillip M, Gat-Yablonski G. **Different patterns of human serum procollagen C-proteinase enhancer1 (PCPE1).** *Clin Chim Acta*. 2009 May; 403(1-2):76-80. (IF 3.0)
99. Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R, Kaufman B. **Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients.** *Am J Clin Oncol*. 2009 Jun 26. [Epub ahead of print](IF 1.8)
100. Zippel DB, Shapira R, Kuchuk I, Goitein D, Winkler E, Papa MZ, Schachter J. **Outcome of thick (> 4 mm) node-negative melanomas.** *Isr Med Assoc J*. 2009 Nov; 11(11):669-72.(IF 0.6)
101. Sagi L, Amichai B, Barzilai A, Weitzen R, Trau H. **Pancreatic panniculitis and carcinoma of the pancreas.** *Clin Exp Dermatol*. 2009 Jul;34(5):e205-7. (IF 1.8)
102. Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. **The diagnostic and prognostic value of ProGRP in lung cancer.** *Anticancer Res*. 2009 Nov;29(11):4827-32 (IF 1.4)
103. Efrati O, Sadeh-Gornik U, Modan-Moses D, Barak A, Szeinberg A, Vardi A, Paret G, Toren A, Vilozni D, Yahav Y. **Flexible bronchoscopy and bronchoalveolar lavage in pediatric patients with lung disease.** *Pediatr Crit Care Med*. 2009 Jan;10(1):80-4 (IF 1.8)
104. Eldar AH, Futerman B, Abrahami G, Attias D, Barak AB, Burstein Y, Dvir R, Gabriel H, Horovitz J, Kapelushnik J, Kaplinsky H, Miskin H, Sthoeger D, Toren A, Vilk-Revel S, Weintraub M, Yaniv I, Linn S, Arush MB. **Burkitt lymphoma in children: the Israeli experience.** *J Pediatr Hematol Oncol*. 2009 Jun; 31(6):428-36.
105. Small RM, Lubezky N, Shmueli E, Figer A, Aderka D, Nakache R, Klausner JM, Ben-Haim M. **Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.** *J Surg Oncol*. 2009 Feb 1;99(2):93-8. (IF 2.5)
106. Hodish I, Tal R, Shaish A, Varda-Bloom N, Greenberger S, Rauchwerger A, Breitbart E, Bangio L, Ben-Shushan D, Pfeffer R, Feder B, Waitsman A, Barshack I, Goldberg I, Mazaki-Tovi S, Peled M, Harats D. **Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK.** *Cancer Biol Ther*. 2009 Mar;8(5):424-32. (IF 2.8)
107. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. **Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.** *J Oral Maxillofac Surg*. 2009 Apr;67(4):850-5.
108. Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S, Friedman E. **Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.** *Fam Cancer*. 2009; 8(2):127-33.(IF 2.1)
109. Cohen S, Laitman Y, Kaufman B, Milgrom R, Nir U, Friedman E. **SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and**

- ovarian cancer in Jewish women.** *Fam Cancer.* 2009; 8(2):135-44. Epub 2008 Sep 27. (IF 2.1)
110. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S. **Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.** *Lancet Oncol.* 2009 Jun; 10(6):581-8.(IF 13.3)
 111. Menachem TD, Laitman Y, Kaufman B, Friedman E. **The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.** *Fam Cancer.* 2009; 8(4):399-402. (IF 2.1)
 112. Kaufman B, Laitman Y, Gronwald J, Lubinski J, Friedman E **Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals.** *Genet Test Mol Biomarkers.* 2009 Aug; 13(4):465-9.
 113. Kaufman B, Laitman Y, Gronwald J, Winqvist R, Irmejs A, Lubinski J, Pylkäs K, Gardovskis J, Miklasevics E, Friedman E. **Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.** *Fam Cancer.* 2009; 8(4):473-8. (IF 2.1)
 114. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. **Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.** *J Clin Oncol.* 2009 Nov 20; 27(33):5529-37. (IF 1.8)
 115. Aviv V, Meivar-Levy I, Rachmut IH, Rubinek T, Mor E, Ferber S. **Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process.** *J Biol Chem.* 2009 Nov 27; 284(48):33509-20. (IF 5.5)
 116. Bakhanashvili M, Grinberg S, Bonda E, Rahav G. **Excision of nucleoside analogs in mitochondria by p53 protein.** *AIDS.* 2009 Apr 27;23(7):779-88.(IF 5.5)
 117. Bruchim I, Israeli O, Mahmud SM, Aviram-Goldring A, Rienstein S, Friedman E, Ben-Baruch G, Gotlieb WH. **Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma.** *Cancer Genet Cytogenet.* 2009 Apr 15; 190(2):66-70.
 118. Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, Ben-Baruch G. **Uterine leiomyosarcoma: does the primary surgical procedure matter?** *Int J Gynecol Cancer.* 2009 Feb; 19(2):257-60.(IF 1.9)
 119. Korach J, Perri T, Beiner M, Davidzon T, Fridman E, Ben-Baruch G **Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.** *Int J Gynecol Cancer.* 2009 Jul; 19(5):830-3.
 120. Mardor Y, Last D, Daniels D, Shneor R, Maier SE, Nass D, Ram Z **Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring** *J Pharmacol Exp Ther.* 2009 Aug; 330(2):520-5. (IF 4.3)
 121. Menczer J, Chetrit A, Sadetzki S; National Israel Ovarian Cancer Group **The effect of symptom duration in epithelial ovarian cancer on prognostic factors.** *Arch Gynecol Obstet.* 2009 Jun;279(6):797-801. (IF 0.7)

122. Mandelzweig L, Novikov I, Sadetzki S. **Smoking and risk of glioma: a meta-analysis.** *Cancer Causes Control.* 2009 Jul 1. [Epub ahead of print]
123. Menczer J, Chetrit A, Sadetzki S; National Israel Ovarian Cancer Group. **Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel.** *Eur J Gynaecol Oncol.* 2009;30(4):375-8 (IF 0.6)
124. Menczer J, Barchana M, Chetrit A, Liphshitz I, Sadetzki S. **Incidence rates of cervical carcinoma among first- and second-generation women of North African origin in Israel.** *Int J Gynecol Cancer.* 2009 Dec; 19(9):1606-9.(IF 1.9)

* (IF - Impact Factor top 500 scientific journals)